Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2013-09-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Flow Mediated Dilation in Response to Black Tea
NCT02273323
The Effect of Tea on Vascular Function and Insulin Sensitivity
NCT02777853
Tea and Forearm Blood Flow
NCT02328339
Tea's Effect on Atherosclerosis Pilot Study (TEA Study)
NCT00120107
The Effect of Tea Breaks on Cerebrovascular Perfusion During Desk Work
NCT03953391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Black tea extract
Spray dried aqueous extract of a representative batch of black tea
Black tea extract
Black tea extract
Positive control
Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
Positive control
Positive control
Placebo
Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Black tea extract
Black tea extract
Positive control
Positive control
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having body mass index (BMI) of between 18.0 and 30.0 kg/m2 (inclusive)
* Non-smokers (\> 2 years)
* Non-tea drinkers (less or equal 1 cup/week)
* Limited alcohol intake (less or equal 21 units/week)
* Systolic blood pressure less or equal 160 mmHg and/or diastolic blood pressure less or equal 100 mmHg at screening
* Brachial artery can be imaged using ultrasound and at screening FMD value is within the expected range as judged by the PI
* Judged to be in good health on the basis of medical history, physical examination and routine laboratory tests (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, highly sensitive C-reactive protein).
40 Years
65 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sprim Advanced Life Sciences
OTHER
Unilever R&D
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lorenzo Ghiadoni, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pisa, Internal medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliero-Universitaria Pisana, Centro di Farmacologia Clinicaper la Sperimentazione dei Farmaci
Pisa, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REF-BEV-1134
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.